What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Alliance for Clinical Trials in Oncology

Home
United States
Boston, MA
Alliance for Clinical Trials in Oncology

Alliance develops and conducts cancer clinical trials as part of NCI National Clinical Trials Network

12/22/2025

💡 Driving Change in Clinical Trials
At the 2025 Alliance Fall Group Meeting, the CCP Worta McCaskill-Stevens, MD, MS Symposium brought together thought leaders to explore “Change Makers Redefining Clinical Trials.”
✅ Moderator: Matthew Banegas, PhD (UC San Diego School of Medicine)
✅ Speakers:
• Linda Bulone, RN, OCN, CCRC – Queens Hospital Cancer Center
• Peggy Kemeny, MD – Icahn School of Medicine at Mount Sinai
• Electra Paskett, PhD – The Ohio State University Comprehensive Cancer Center
• Lucy Gansauer, MSN, RN, OCN, CCRP – SWOG Cancer Research Network
The symposium highlighted strategies to improve diversity, engagement, and accrual in cancer research, emphasizing that change is an opportunity to advance meaningful science.
👏 Thank you to all participants for inspiring progress in clinical trial participation!
Learn more: https://bit.ly/2025-Awards

12/19/2025

The Alliance Cancer Control Program has renamed the Health Disparities Committee to the Populations, Education, Access, and Research (PEAR) Committee.
Why the change?
✅ Better reflects the committee’s mission
✅ Focus on addressing population needs
✅ Expanding education and improving access
✅ Supporting research initiatives across the organization

The PEAR Committee will continue to guide strategies that advance equity and innovation in cancer care.
🔗 Learn more: https://bit.ly/pear25

12/18/2025

🌟 Honoring Leadership in Psycho-Oncology
At the 2025 Alliance Fall Group Meeting, Sharon Manne, PhD, delivered the 24th Annual Jimmie Holland Lecture, sponsored by the Alliance Health Outcomes Committee. This lectureship celebrates the legacy of Dr. Jimmie Holland and recognizes individuals who have made transformative contributions to psycho-oncology.
Dr. Manne, Professor at Robert Wood Johnson Medical School and Co-Director of the Cancer Survivorship and Outcomes Center at Rutgers Cancer Institute, is an internationally recognized expert in psychological interventions for cancer patients and families. Her research has advanced evidence-based strategies to improve coping, mental health, and quality of life across the cancer continuum.
👏 Congratulations, Dr. Manne, for your decades of impactful research, mentorship, and leadership in survivorship care!
Learn more: https://bit.ly/2025-Awards

12/17/2025

At the Alliance for Clinical Trials in Oncology, we share stories that highlight the progress and impact of cancer research. Click to see some of our recent media coverage. https://bit.ly/Media-2025

12/17/2025

🌍 Alliance at ESMO 2025 – Driving Progress in Cancer Care
At the ESMO Congress in Berlin, Alliance shared exciting research that’s making a real difference for patients:
✅ PRESTO – A new approach to help men with high-risk prostate cancer live longer and better
✅ PATINA – Adding palbociclib improves quality of life for people with advanced breast cancer
✅ ATOMIC – Immunotherapy shows promise for certain colon cancers
✅ CABINET – A treatment option for rare neuroendocrine tumors
These studies reflect our mission: better treatments, better lives.
🔗 Learn more: https://bit.ly/ESMO25

12/16/2025

🎉 Celebrating Excellence in Cancer Research!
At the 2025 Alliance Fall Group Meeting, Dr. Richard Stone of Dana-Farber Cancer Institute and Harvard Medical School received the prestigious Richard L. Schilsky CALGB Achievement Award 🏅
His groundbreaking work in leukemia research and clinical trial innovation continues to shape the future of oncology. His inspiring lecture: “CALGB/Alliance: Make Friends, Enhance Cancer, Cure Cancer.”
👏 Congratulations, Dr. Stone, for your leadership and impact!
🔗 Learn more: https://bit.ly/2025-Awards

12/15/2025

📣 Exciting news from the Alliance for Clinical Trials in Oncology! A new study in JAMA Oncology has revealed that a blood-based biomarker can guide the use of anti-inflammatory drugs (NSAIDs) after surgery and chemotherapy to reduce the risk of colon cancer recurrence. Here's why this is a important:

💡Personalized Prevention: By identifying patients at higher risk through a simple blood test, clinicians can target NSAID therapy more effectively—maximizing benefit while minimizing unnecessary exposure.
💡Innovative Approach: This strategy isn’t “one-size-fits-all.” It aligns cancer prevention efforts with the individual biology of each patient, marking a leap forward in precision oncology.
💡Potential for Impact: Colon cancer recurrence remains a significant challenge. Tailoring NSAID therapy based on biomarker results could transform long-term outcomes.

Read the full news release at https://bit.ly/JAMA-NSAID.

12/15/2025

The Alliance for Clinical Trials in Oncology has chosen its Most Significant Manuscripts from Sept 2024–Aug 2025, showcasing groundbreaking work that is shaping cancer care.
📌 Key Highlights:
✅ AMBASSADOR: Immunotherapy after surgery improves disease-free survival in urothelial carcinoma (NEJM).
✅ CABINET: Cabozantinib, a targeted cancer therapy drug called a tyrosine kinase inhibitor, significantly boosts progression-free survival in neuroendocrine tumors (NEJM).
✅ CALGB-80405: Plant-based diet helps people with metastatic colorectal cancer live longer (JNCI).
✅ A091802: Adding the monoclonal antibody cetuximab to the immunotherapy drug avelumab improves outcomes for people with advanced skin cancer (JCO).

🔗 Read the full list of top four papers and three honorable mentions: https://bit.ly/Top4-2025

12/12/2025

🔍 New Clinical Trial Spotlight!
Dean Shumway, MD, of the Mayo Clinic is leading Alliance A012301 (LoTam), a study comparing 💊 low-dose tamoxifen versus 🔄 usual hormonal therapy for post-menopausal women with early-stage HER2-negative breast cancer.
This research has the potential to 📖 influence future treatment guidelines and 💗 improve quality of life for patients by evaluating a lower-dose approach.
🔗 Learn more: https://bit.ly/Alliance-A012301

12/11/2025

📢 New Publication Alert!
A study by Alliance researchers and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications for treating acute myeloid leukemia (AML) may be outdated and overly simplistic.
✅ Clinical Implication: This research suggests that treatment decisions should move beyond chronological age and instead consider biologic and disease-specific factors—potentially transforming how AML therapy is personalized for better outcomes.
🔗 Read the news release: https://bit.ly/AML-Study
🔗 Read the full study in Nature Leukemia: https://www.nature.com/articles/s41375-025-02644-0

12/10/2025

At this year’s San Antonio Breast Cancer Symposium, Alliance for Clinical Trials in Oncology and Alliance Foundation Trial members are presenting 17 research abstracts. https://bit.ly/SABCS-25

12/10/2025

🌟 New Trial Now Enrolling! 🌟
Dr. Angela Bradbury of University of Pennsylvania Abramson Cancer Center leads Alliance A232301CD, a study exploring whether a 💬 digital chatbot intervention can be as effective as 📡 standard remote genetic services in increasing counseling uptake among adolescent and young adult cancer patients.
🔗 Learn more: https://bit.ly/AllianceA232301CD

Address

Alliance For Clinical Trials In Oncology, Office Of The Group Chair 221 Longwood Avenue, Room 108
Boston, MA
02115

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+16177328919

Website

http://www.AllianceforClinicalTrialsinOncology.org/

Alerts

Be the first to know and let us send you an email when Alliance for Clinical Trials in Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.